PT - JOURNAL ARTICLE AU - Khazar Ahmadi AU - Joana B. Pereira AU - David Berron AU - Jacob Vogel AU - Silvia Ingala AU - Olof T. Strandberg AU - Shorena Janelidze AU - Frederik Barkhof AU - Josef Pfeuffer AU - Linda Knutsson AU - Danielle van Westen AU - Henk J.M.M. Mutsaerts AU - Sebastian Palmqvist AU - Oskar Hansson TI - Cerebral hypoperfusion is a late pathological event in the course of Alzheimer’s disease AID - 10.1101/2021.07.02.21259911 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.02.21259911 4099 - http://medrxiv.org/content/early/2021/07/05/2021.07.02.21259911.short 4100 - http://medrxiv.org/content/early/2021/07/05/2021.07.02.21259911.full AB - Although several studies have shown decreased cerebral blood flow (CBF) in Alzheimer’s disease (AD), the role of hypoperfusion in the disease pathogenesis remains unclear. Combining arterial spin labeling MRI, positron emission tomography, and biomarkers of cerebrospinal fluid, we investigated the associations between CBF and the key mechanisms in AD including amyloid-β (Aβ) and tau pathology, synaptic dysfunction and axonal degeneration. Further, we applied a disease progression modeling to characterize the temporal sequence of different AD biomarkers. Lower perfusion was observed in the temporo-occipito-parietal regions in the Aβ-positive cognitively impaired compared to both the Aβ-positive and Aβ-negative cognitively unimpaired individuals. In participants along the AD spectrum (those with Aβ pathology regardless of their cognitive status), CBF was inversely associated with tau and synaptic dysfunction, but not Aβ, in similar cortical regions. Moreover, the disease progression modeling revealed that CBF disruption followed the abnormality of biomarkers of Aβ, tau and brain atrophy. These findings indicate that tau tangles and synaptic degeneration are more closely connected with CBF changes rather than Aβ pathology. This supports the notion that hypoperfusion is not an early event associated with the build-up of Aβ during the preclinical phase of AD.Competing Interest StatementO.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche. J.P. is an employee of Siemens Healthcare. All other authors report no competing interests.Clinical TrialNCT03174938Funding StatementThe present study was supported by the European Research Council (grant no. 311292), the Swedish Research Council (grants no. 2016-00906 and 2018-02052), the Knut and Alice Wallenberg Foundation (grant no. 2017-0383), the Marianne and Marcus Wallenberg Foundation (grant no. 2015.0125), the Swedish Alzheimer Foundation (grant no. AF-745911), the Swedish Brain Foundation (grant no. FO2019-0326), the Swedish federal government under the ALF agreement (grants no. 2018-Projekt0279 and 2018-Projekt0226) and the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinsons disease) at Lund University. F.B. was supported by the NIHR biomedical research Centre at UCLH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants gave written informed consent, and the study was approved by the Ethical Review Board in Lund, Sweden.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data will be shared by request from a qualified academic investigator for the sole purpose of replicating procedures and results presented in the article as long as data transfer is in agreement with EU legislation on the general data protection regulation and decisions by the Ethical Review Board of Sweden and Region Skåne, which should be regulated in a material transfer agreement.